Strategic Advocates »

Crispr Therapeutics shares owned by Strategic Advocates

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Strategic Advocates from 13F filings

Historical chart of Strategic Advocates investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Strategic Advocates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Strategic Advocates

Quarter filed Position value Share count Share price at filing
2025-09-30 $34k 525 64.81

More positions owned by Strategic Advocates

State Street Spdr S&p Kensho New Economies Composite Etf Etf (KOMP)
Invesco Qqq Trust Series I Etf (QQQ)
Vanguard Intermediate-term Bond Etf Etf (BIV)
Invesco S&p 500 Pure Value Etf Etf (RPV)
Ishares Core Msci Emerging Markets Etf Etf (IEMG)
State Street Spdr Portfolio Long Term Corporate Bond Etf Etf (SPLB)
Vanguard S&p Small-cap 600 Growth Etf Etf (VIOG)
Ishares 1-5 Year Investment Grade Corporate Bond Etf Etf (IGSB)
Nvidia Corporation Stock (NVDA)
Apple Stock (AAPL)
Palantir Technologies Inc Cl A Stock (PLTR)
Tesla Stock (TSLA)
Pimco 0-5 Year High Yield Corporate Bond Index Exchange-traded Fund Etf (HYS)
Amazon Stock (AMZN)
Meta Platforms Inc Cl A Stock (META)

View all positions for Strategic Advocates

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Capital Research and Management Company - Division 3
Orbis Allan Gray
State Street Corporation
T. Rowe Price Investment Management
UBS Group
Vanguard Group
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
Geode Capital Management
Susquehanna International
Sr One Capital Management
Citadel Advisors
FMR

View all funds holding Crispr Therapeutics